3rd annual symposium on Self Monitoring of Blood Glucose (SMBG) applications and beyond, May 7-8, 2010, London, UK

Diabetes Technology and Therapeutics

Volumn 12, Issue 11, 2010, Pages 859-872

  Lalic, Nebojsa M ^a,b   Landers, Bernhard ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c Center for General Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DAPAGLIFLOZIN; EXENDIN 4; FRUCTOSAMINE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN GLARGINE; INSULIN RECEPTOR; LIRAGLUTIDE; METFORMIN; ROSIGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA; TASPOGLUTIDE; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; BLOOD GLUCOSE MONITORING; CANCER RISK; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; COMPUTER PROGRAM; CONFERENCE PAPER; DIABETES CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH BEHAVIOR; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDIA; INSULIN PUMP; INSULIN TREATMENT; INTERMETHOD COMPARISON; LIFESTYLE MODIFICATION; MEDICAL PRACTICE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREATITIS; PATIENT ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SELF MONITORING; STUDY DESIGN; UNITED KINGDOM; URINARY TRACT INFECTION; WEIGHT GAIN;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GUIDELINES AS TOPIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 78649358295     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0165     Document Type: Conference Paper

References (51)

1. Riddle MC: Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122:844-846.
2. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373:1765-1772.
3. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471.
4. Erratum in N Engl J Med 2007;357:100.
5. Noel RA, Braun DK, Patterson RE, Bloomgren GL: Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-838.
6. th Scientific Sessions, 2009. professional.diabetes. org/Abstracts-Display.aspx?TYP1&CID74461 (accessed September 13, 2010).
7. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Dia-betologia 2009;52:1766-1777.
8. Karter AJ, Parker MM, Moffet HH, Spence MM, Chan J, Ettner SL, Selby JV: Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006;29:1757-1763.
9. Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, Holman R, Kinmonth AL, Neil A: Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007;335:132-141.
10. American Diabetes Association: Standards of medical care in diabetes\2010. Diabetes Care 2010 33(Suppl 1):S11-S61.
11. Erratum in Diabetes Care 2010; 33, 692.
12. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 2004;47:969-975; discussion 976-977. (Pubitemid 38918154)
13. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Ja-cober SJ: Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-386.
14. NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM: Effect of nateglinide on the incidence of diabetes and car diovascular events. N Engl J Med 2010;362:1463-1476.
15. Erratum in N Engl J Med 2010;362:1748.
16. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK; 4-T Study Group: Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-1747.
17. th Scientific Sessions, 2010. professional.diabetes.org/admin/UserFiles/file/SciSessions/ 2010%20Abstracts/2010%20ADA%20LB% 20Abstracts.pdf (accessed September 13, 2010).
18. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglyce-mia in patients with type 2 diabetes. JAMA 2006;295:1681-1687.
19. Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, Owens DR: Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy.Diabetologia 2010;53:562-571.
20. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44:968-983.
21. Zoppini G, Verlato G, Targher G, Bonora E, Trombetta M, Muggeo M: Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study. Diabetes Me-tab Res Rev 2008;24:624-628
22. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617-621.
23. Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M: Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:813-819.
24. 1c. Diabetes Care 2003;26: 881-885.
25. Di Carli MF, Hachamovitch R: Should we screen for occult coronary artery disease among asymptomatic patients with diabetes? J Am Coll Cardiol 2005;45:50-53.
26. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nus-selder W: Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007;167:1145-1151.
27. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-636.
28. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
29. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efend́ic S, Rydén L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359: 2140-2144.
30. Anselmino M, Ohrvik J, Malmberg K, Standl E, Rydén L; Euro Heart Survey Investigators: Glucose lowering treatment in patients with coronary artery disease is prog-nostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 2008;29:177-184.
31. Gitt AK, Towae F, Juenger C, Zeymer U, Zahn R, Senges J: Recognition of abnormal glucose metabolism and its impact on treatment in patients with acute myocardial infarction in Germany: results of the SWEETHEART Registry [abstract 5608]. Circulation 2009;120:S1127.
32. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591.
33. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
34. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
35. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friede-wald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
36. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group: Lir-aglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
37. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davis M; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-1456.
38. Courrèges JP, Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Bugáñová I, Madsbad S: Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 2008;25:1129-1131.
39. Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, Verhoeven R, Bugánová I, Madsbad S: Lir-aglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglyce-mia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-1610.
40. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109: 962-965.
41. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ: GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myo-cardial infarction in mice. Diabetes 2009;58:975-983.
42. Yadav D, Lowenfels AB: Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review. Pancreas 2006;33:323-330.
43. Erratum in Pancreas 2007;34:174.
44. Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Mølck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M: Glu-cagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-1486.
45. Pan CQ, Buxton JM, Yung SL, Tom I, Yang L, Chen H, MacDougall M, Bell A, Claus TH, Clairmont KB, Whelan JP: Design of a long acting peptide functioning as both a glu-cagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J Biol Chem 2006;281:12506-12515.
46. Aicher T, Anderson D, Boyd S, Chicarelli M, Condroski K, DeWolf W Jr, Fell JB, Fischer J, Frank M, Galbraith S, Garrey R, Gunawardana I, Hinklin R, Hirsch J, Lee P, Neitzel N, Pratt S, Singh A, Thomas L, Turner T, Voegtli W, Wallace E, Williams L: Discovery of ARRY-588, a novel glucokinase activator with potent glucose lowering activity in animal models of type 2 diabetes mellitus. ARRAY Biopharma Inc. www.arraybiopharma.com/-documents/Publication/ PubAttachment288.pdf (accessed September 13, 2010).
47. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huber R; INCB13739-202 Principal Investigators. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin mono-therapy. Diabetes Care 2010;33:1516-1522.
48. Manchem VP, Goldfine ID, Kohanski RA, Cristobal CP, Lum RT, Schow SR, Shi S, Spevak WR, Laborde E, Toavs DK, Villar HO, Wick MM, Kozlowski MR: A novel small molecule that directly sensitizes the insulin receptor in vitro and in vivo. Diabetes 2001;50:824-830.
49. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-2233.
50. Shashaj B, Busetto E, Sulli N: Benefits of a bolus calculator in pre-and postprandial glycaemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII). Diabet Med 2008;25:1036-1042.
51. th Scientific Sessions, 2010. professional.diabetes.org/Abstracts-Display.aspx?TYP1& CID79483 (accessed September 13, 2010).